Clinical trial
Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.
NCT00916201 is registered in ClinicalTrials.gov with Central Institute of Mental Health, Mannheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.
- Lead sponsor
- Central Institute of Mental Health, Mannheim
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- January 31, 2025
- Completion date
- January 31, 2025
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.